The Whole World is Dancing to "Chicken Banana" TikTok's New Obsession – And Already One of 2025's Biggest Viral Hits

Share

Listen to the song here: https://www.youtube.com/watch?v=ig7EKb6BrQk

May 13, 2025 – What do a chicken, a banana, and billions of views have in common? Chicken Banana — the viral hit from Swedish duo Maads and Bruno (Crazy Music Channel) — has exploded online to become one of 2025’s biggest TikTok trends.

The numbers are staggering: 10 billion views globally across all major platforms, with 2 billion views on TikTok, 6.5 billion on YouTube Shorts, and 1.9 million TikTok creations. The official video has topped 34 million views, with streams nearing 300,000 per day. Chicken Banana isn’t just a song — it’s a cultural moment.

It’s simple, silly, and catchy choreography has sparked a global dance movement. From kids and families to farmers and grandparents, the trend has crossed age and cultural lines. Celebrities like @ginjiro_koyama and @ciizezphr, plus celeb families like @carlosferiag and @lafamiliagomes, have all joined the wave.

Mainstream media has picked it up too, with features on Germany’s Frühstücksfernsehen, Dancing with the Stars Austria, and even in German Schlager pop. The trend’s universality and low barrier to entry have helped it thrive everywhere.

Plenty of companies haven’t missed out - everyone from entertainment groups to video game franchises and even supermarkets have jumped on the Chicken Banana trend, putting their own creative spin on it.

So why is it so irresistible? A bouncy electro-house beat, a modulated bassline, and a looping male voice chanting “Chicken Banana” with an Indian flair — it’s hypnotic and absurd in the best way.

To truly understand TikTok, you need to know Chicken Banana. And once you do, you'll suddenly understand a whole lot more.

- Video is available at AP

Download & Stream:  https://crazymusicchannel.lnk.to/ChickenBanana

TikTok: https://www.tiktok.com/music/Chicken-Banana-7465696476092042006

SOCIALS:

YouTube: https://www.youtube.com/channel/UCY27hxWP4QRIvTnJvrfGJoA

Instagram: https://www.instagram.com/crazymusicchannel/

TikTok: https://www.tiktok.com/@crazymusicchannel

SoundCloud: https://soundcloud.com/crazymusicchannel

To view this piece of content from www.youtube.com, please give your consent at the top of this page.

Contacts

Sony Music / B1 Records
Iris Mengi - iris.mengi@sonymusic.com

Links

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

Vyoma’s first Space Domain Awareness satellite has reached orbit13.1.2026 12:34:15 CET | Press Release

Munich, 13. January 2026 - Vyoma, a Germany-based company providing Space Domain Awareness (SDA) capabilities, has launched its pioneering surveillance satellite, Flamingo-1, on Sunday, January 11th, 2026 from Vandenberg Space Force Base, California, USA. It was launched aboard the Twilight rideshare mission with SpaceX via Germany-based launch integrator Exolaunch. The satellite was deployed to its operational Sun-synchronous orbit of approximately 500-km in altitude. This marks a significant achievement for the company, which patented the operational concept of an optimized SDA mission. Flamingo-1, equipped with an optical sensor for space-based space surveillance, is a gamechanger for Europe, strengthening SDA efforts directly from orbit. The advanced optical instrument will detect, track and characterize space objects, such as debris and other satellites. Crucially, it will allow Vyoma and its customers to follow up on manoeuvring objects and derive insights into adversary actions

Acousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced Ototoxicity8.1.2026 09:00:00 CET | Press Release

Tübingen, Germany, January 8, 2026 Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ACOU085 (INN: Bimokalner) is a proprietary, first-in-class small molecule that has demonstrated robust and reproducible efficacy across multiple preclinical hearing loss models, including drug-induced ototoxicity. The PROHEAR Study is a double-blind, randomized, placebo-controlled, split-body, multicenter Phase 2 trial. It enrolled young male patients with metastatic testicular cancer who are scheduled to receive cisplatin-based chemotherapy. While cisplatin is a highly effective chemotherapeutic agent, cumulative doses of ≥300 mg/m² lead to clinically meaningful, permanent hearing loss in the majority of patients. Fifteen leading university hospitals in Germany are participating in this interdisciplinary study. Patients are randomized

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye